SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.
autoantibodies
autoimmunity
dermatomyositis
polymyositis
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
13
09
2021
accepted:
23
01
2022
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
7
4
2022
Statut:
ppublish
Résumé
To evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes by flow cytometry as a type I interferon biomarker in idiopathic inflammatory myopathies (IIM). We performed a retrospective analysis of adult and paediatric patients with the diagnosis of IIM. SIGLEC1 expression was assessed by flow cytometry and was compared with Physician Global Assessment or Childhood Myositis Assessment Scale disease activity scores. Mann Whitney U test and receiver operating characteristic curves were used for cross-sectional data analysis (n=96), two-level mixed-effects linear regression model for longitudinal analyses (n=26, 110 visits). Response to treatment was analysed in 14 patients within 12 months, using Wilcoxon test. SIGLEC1 was compared with interferon-stimulated gene 15/MxA status by immunohistochemical staining of muscle biopsies (n=17). 96 patients with adult (a) and juvenile (j) dermatomyositis (DM, n=38), antisynthetase syndrome (AS, n=19), immune-mediated necrotising myopathy (IMNM, n=8), inclusion body myositis (IBM, n=9) and overlap myositis (n=22) were included. SIGLEC1 distinguished significantly between active and inactive disease with an area under the curve of 0.92 (95% CI 0.83 to 1) in DM and correlated with disease activity longitudinally (aDM: standardised beta=0.54, p<0.001; jDM: standardised beta=-0.70, p<0.001). Response to treatment in DM was associated with a decreasing SIGLEC1 (p<0.01, Wilcoxon test). SIGLEC1 was found upregulated in 8 of 19 patients with AS, 2 of 9 patients with IBM but not in IMNM. SIGLEC1 is a candidate biomarker to assess type I interferon activity in IIM and proved useful for monitoring disease activity and response to treatment in juvenile and adult DM.
Identifiants
pubmed: 35177553
pii: rmdopen-2021-001934
doi: 10.1136/rmdopen-2021-001934
pmc: PMC8860073
pii:
doi:
Substances chimiques
Interferon Type I
0
SIGLEC1 protein, human
0
Sialic Acid Binding Ig-like Lectin 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Arthritis Rheum. 2004 May;50(5):1595-603
pubmed: 15146430
Brain. 2018 Jun 1;141(6):1609-1621
pubmed: 29741608
Genes Immun. 2012 Apr;13(3):207-13
pubmed: 21881594
Curr Rheumatol Rep. 2010 Jun;12(3):198-203
pubmed: 20425524
J Rheumatol. 2003 Mar;30(3):603-17
pubmed: 12610824
Ann Rheum Dis. 2017 Dec;76(12):1955-1964
pubmed: 29079590
N Engl J Med. 2020 Jan 16;382(3):211-221
pubmed: 31851795
Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119
pubmed: 30060040
Lupus. 2020 Dec;29(14):1914-1925
pubmed: 33081587
Rheumatology (Oxford). 2021 Aug 13;:
pubmed: 34387304
Curr Opin Neurol. 2020 Oct;33(5):590-603
pubmed: 32852298
Neurology. 2020 Jul 7;95(1):e70-e78
pubmed: 32487712
Blood. 2006 Apr 15;107(8):3229-34
pubmed: 16368889
Infection. 2021 Aug;49(4):757-762
pubmed: 33825125
RMD Open. 2019 Feb 26;5(1):e000811
pubmed: 30886734
Neurology. 2017 Jan 31;88(5):493-500
pubmed: 28039312
Neuropathol Appl Neurobiol. 2017 Feb;43(1):62-81
pubmed: 28075491
Best Pract Res Clin Rheumatol. 2017 Jun;31(3):321-333
pubmed: 29224674
J Mol Med (Berl). 2017 Jul;95(7):753-765
pubmed: 28357476
Arthritis Rheum. 2007 Nov;56(11):3784-92
pubmed: 17968926
Arthritis Rheum. 2008 Apr;58(4):1136-45
pubmed: 18383365
Arthritis Rheum. 2009 Nov;60(11):3436-46
pubmed: 19877033
Neuropathol Appl Neurobiol. 2019 Aug;45(5):513-522
pubmed: 30267437
BMC Musculoskelet Disord. 2015 Sep 17;16:257
pubmed: 26382217
Neuromuscul Disord. 2018 Jan;28(1):87-99
pubmed: 29221629
Arthritis Rheumatol. 2021 May;73(5):858-865
pubmed: 33258553
Front Neurol. 2019 Jun 04;10:554
pubmed: 31214105
Rheumatology (Oxford). 2017 Sep 1;56(9):1618-1626
pubmed: 28859328
Neurology. 2019 Sep 17;93(12):e1193-e1204
pubmed: 31434690
J Clin Rheumatol. 2014 Jan;20(1):47-8
pubmed: 24356484
Mol Med. 2007 Jan-Feb;13(1-2):59-68
pubmed: 17515957
Immun Inflamm Dis. 2020 Mar;8(1):106-123
pubmed: 32031762
Arthritis Rheum. 2012 Dec;64(12):4078-86
pubmed: 22886447
Clin Chem. 2005 Dec;51(12):2341-7
pubmed: 16214828
Pediatr Allergy Immunol. 2021 Apr;32(3):621-625
pubmed: 33099809
RMD Open. 2016 Dec 30;2(2):e000292
pubmed: 28123773
Arthritis Rheumatol. 2020 Jan;72(1):195-197
pubmed: 31487101
Br J Dermatol. 2017 May;176(5):1224-1230
pubmed: 27564228
Scand J Immunol. 2016 Aug;84(2):100-9
pubmed: 27173897
Curr Opin Rheumatol. 2019 Nov;31(6):634-642
pubmed: 31464706
J Clin Immunol. 2017 Feb;37(2):123-132
pubmed: 27943079
JAMA Neurol. 2018 Dec 1;75(12):1528-1537
pubmed: 30208379
Ann Rheum Dis. 2013 Oct;72(10):1639-45
pubmed: 23117242
Hum Genomics Proteomics. 2009 Nov 17;2009:
pubmed: 20948567
Arthritis Rheum. 2007 Mar;56(3):1010-20
pubmed: 17328080
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57
pubmed: 22588740
Rheumatology (Oxford). 2020 Nov 1;59(11):3435-3442
pubmed: 32357246
Lancet Neurol. 2013 Dec;12(12):1159-69
pubmed: 24183309
Clin Immunol. 2006 Sep;120(3):319-25
pubmed: 16859997
Front Immunol. 2019 May 09;10:1040
pubmed: 31143183